News | July 24, 2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
The inspection closed with zero observations
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
New Board of Directors and management team at Suven Pharma also appointed
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Subscribe To Our Newsletter & Stay Updated
